1. Home
  2. PHUN vs CTOR Comparison

PHUN vs CTOR Comparison

Compare PHUN & CTOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PHUN
  • CTOR
  • Stock Information
  • Founded
  • PHUN 2009
  • CTOR 2021
  • Country
  • PHUN United States
  • CTOR United States
  • Employees
  • PHUN N/A
  • CTOR N/A
  • Industry
  • PHUN EDP Services
  • CTOR
  • Sector
  • PHUN Technology
  • CTOR
  • Exchange
  • PHUN Nasdaq
  • CTOR NYSE
  • Market Cap
  • PHUN 88.8M
  • CTOR 89.9M
  • IPO Year
  • PHUN N/A
  • CTOR N/A
  • Fundamental
  • Price
  • PHUN $3.92
  • CTOR $1.28
  • Analyst Decision
  • PHUN Strong Buy
  • CTOR Strong Buy
  • Analyst Count
  • PHUN 3
  • CTOR 2
  • Target Price
  • PHUN $13.00
  • CTOR $4.50
  • AVG Volume (30 Days)
  • PHUN 1.1M
  • CTOR 77.8K
  • Earning Date
  • PHUN 03-11-2025
  • CTOR 02-25-2025
  • Dividend Yield
  • PHUN N/A
  • CTOR N/A
  • EPS Growth
  • PHUN N/A
  • CTOR N/A
  • EPS
  • PHUN N/A
  • CTOR N/A
  • Revenue
  • PHUN $3,537,000.00
  • CTOR N/A
  • Revenue This Year
  • PHUN N/A
  • CTOR N/A
  • Revenue Next Year
  • PHUN $93.33
  • CTOR N/A
  • P/E Ratio
  • PHUN N/A
  • CTOR N/A
  • Revenue Growth
  • PHUN N/A
  • CTOR N/A
  • 52 Week Low
  • PHUN $2.85
  • CTOR $0.85
  • 52 Week High
  • PHUN $17.99
  • CTOR $49.00
  • Technical
  • Relative Strength Index (RSI)
  • PHUN 41.98
  • CTOR N/A
  • Support Level
  • PHUN $3.56
  • CTOR N/A
  • Resistance Level
  • PHUN $4.04
  • CTOR N/A
  • Average True Range (ATR)
  • PHUN 0.22
  • CTOR 0.00
  • MACD
  • PHUN -0.01
  • CTOR 0.00
  • Stochastic Oscillator
  • PHUN 46.71
  • CTOR 0.00

About PHUN Phunware Inc.

Phunware Inc is a software company. It is a cloud platform for mobile that provides companies with the products, solutions, and data and services necessary to engage, manage and monetize its mobile application audiences. It derives maximum revenue from United States.

About CTOR CITIUS ONCOLOGY INC

Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.

Share on Social Networks: